Acute and long-term results after intra-arterial thrombolysis of occluded lower extremity bypass grafts using recombinant tissue plasminogen activator for acute limb-threatening ischemia.

Sandeep Khosla, Pankaj Jain, Ravi Manda, Mansour Razminia, Mayra Guerrero, Atul Trivedi, Vasundhara Vidyarthi, Monther Elbazour, Binu Kunjummen, Aziz Ahmed, David Lubell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Occlusion of lower extremity vascular bypass grafts results in acute limb-threatening ischemia. The underlying cause of graft failure generally is distal anastomosis stenosis, and relief of culprit stenosis is a required to maintain long-term patency. Of the three thrombolytic agents used for prolonged infusion to accomplish fibrinolysis, streptokinase was the first to be used and is limited owing to the antigenicity that precludes repeated use. Urokinase had been the mainstay of thrombolytic therapy until it was withdrawn by the U.S. Food and Drug Administration in 1999 because of the potential of transmission of infectious agents during its manufacturing process. Recombinant tissue plasminogen activator (rt-PA) has not been studied adequately to assess safety and efficacy, and there are no standardized dosing guidelines. We report our experience with six patients presenting with acute limb-threatening ischemia attributable to thrombosis of synthetic lower extremity bypass grafts. After thrombolysis using rt-PA (mean bolus dose, 12.2 +/- 3.6 mg; range, 6-15 mg administered over 5 minutes followed by infusion at 2 mg/h for 15.6 +/- 6.4 hours; total dose, 51 +/- 16 mg), successful thrombolysis was achieved in 84% of the patients. The primary patency rate was 75% and the secondary patency rate 100% at 16 weeks. One patient underwent amputation owing to unsuccessful thrombolysis. No major bleeding or vascular complications occurred. We conclude that intra-arterial thrombolysis using rt-PA is a safe and effective therapy for patients with thrombotic occlusion of synthetic lower extremity bypass grafts presenting with acute limb-threatening ischemia and allows a high rate of secondary patency, avoiding amputation.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
JournalAmerican journal of therapeutics
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Tissue Plasminogen Activator
Lower Extremity
Ischemia
Extremities
Transplants
Amputation
Blood Vessels
Pathologic Constriction
Streptokinase
Fibrinolytic Agents
Thrombolytic Therapy
Urokinase-Type Plasminogen Activator
Fibrinolysis
United States Food and Drug Administration
Thrombosis
Guidelines
Hemorrhage
Safety
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Acute and long-term results after intra-arterial thrombolysis of occluded lower extremity bypass grafts using recombinant tissue plasminogen activator for acute limb-threatening ischemia. / Khosla, Sandeep; Jain, Pankaj; Manda, Ravi; Razminia, Mansour; Guerrero, Mayra; Trivedi, Atul; Vidyarthi, Vasundhara; Elbazour, Monther; Kunjummen, Binu; Ahmed, Aziz; Lubell, David.

In: American journal of therapeutics, Vol. 10, No. 1, 01.01.2003, p. 3-6.

Research output: Contribution to journalArticle

Khosla, Sandeep ; Jain, Pankaj ; Manda, Ravi ; Razminia, Mansour ; Guerrero, Mayra ; Trivedi, Atul ; Vidyarthi, Vasundhara ; Elbazour, Monther ; Kunjummen, Binu ; Ahmed, Aziz ; Lubell, David. / Acute and long-term results after intra-arterial thrombolysis of occluded lower extremity bypass grafts using recombinant tissue plasminogen activator for acute limb-threatening ischemia. In: American journal of therapeutics. 2003 ; Vol. 10, No. 1. pp. 3-6.
@article{c84fe6468caa458c9a0405c0878f419e,
title = "Acute and long-term results after intra-arterial thrombolysis of occluded lower extremity bypass grafts using recombinant tissue plasminogen activator for acute limb-threatening ischemia.",
abstract = "Occlusion of lower extremity vascular bypass grafts results in acute limb-threatening ischemia. The underlying cause of graft failure generally is distal anastomosis stenosis, and relief of culprit stenosis is a required to maintain long-term patency. Of the three thrombolytic agents used for prolonged infusion to accomplish fibrinolysis, streptokinase was the first to be used and is limited owing to the antigenicity that precludes repeated use. Urokinase had been the mainstay of thrombolytic therapy until it was withdrawn by the U.S. Food and Drug Administration in 1999 because of the potential of transmission of infectious agents during its manufacturing process. Recombinant tissue plasminogen activator (rt-PA) has not been studied adequately to assess safety and efficacy, and there are no standardized dosing guidelines. We report our experience with six patients presenting with acute limb-threatening ischemia attributable to thrombosis of synthetic lower extremity bypass grafts. After thrombolysis using rt-PA (mean bolus dose, 12.2 +/- 3.6 mg; range, 6-15 mg administered over 5 minutes followed by infusion at 2 mg/h for 15.6 +/- 6.4 hours; total dose, 51 +/- 16 mg), successful thrombolysis was achieved in 84{\%} of the patients. The primary patency rate was 75{\%} and the secondary patency rate 100{\%} at 16 weeks. One patient underwent amputation owing to unsuccessful thrombolysis. No major bleeding or vascular complications occurred. We conclude that intra-arterial thrombolysis using rt-PA is a safe and effective therapy for patients with thrombotic occlusion of synthetic lower extremity bypass grafts presenting with acute limb-threatening ischemia and allows a high rate of secondary patency, avoiding amputation.",
author = "Sandeep Khosla and Pankaj Jain and Ravi Manda and Mansour Razminia and Mayra Guerrero and Atul Trivedi and Vasundhara Vidyarthi and Monther Elbazour and Binu Kunjummen and Aziz Ahmed and David Lubell",
year = "2003",
month = "1",
day = "1",
doi = "10.1097/00045391-200301000-00003",
language = "English (US)",
volume = "10",
pages = "3--6",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Acute and long-term results after intra-arterial thrombolysis of occluded lower extremity bypass grafts using recombinant tissue plasminogen activator for acute limb-threatening ischemia.

AU - Khosla, Sandeep

AU - Jain, Pankaj

AU - Manda, Ravi

AU - Razminia, Mansour

AU - Guerrero, Mayra

AU - Trivedi, Atul

AU - Vidyarthi, Vasundhara

AU - Elbazour, Monther

AU - Kunjummen, Binu

AU - Ahmed, Aziz

AU - Lubell, David

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Occlusion of lower extremity vascular bypass grafts results in acute limb-threatening ischemia. The underlying cause of graft failure generally is distal anastomosis stenosis, and relief of culprit stenosis is a required to maintain long-term patency. Of the three thrombolytic agents used for prolonged infusion to accomplish fibrinolysis, streptokinase was the first to be used and is limited owing to the antigenicity that precludes repeated use. Urokinase had been the mainstay of thrombolytic therapy until it was withdrawn by the U.S. Food and Drug Administration in 1999 because of the potential of transmission of infectious agents during its manufacturing process. Recombinant tissue plasminogen activator (rt-PA) has not been studied adequately to assess safety and efficacy, and there are no standardized dosing guidelines. We report our experience with six patients presenting with acute limb-threatening ischemia attributable to thrombosis of synthetic lower extremity bypass grafts. After thrombolysis using rt-PA (mean bolus dose, 12.2 +/- 3.6 mg; range, 6-15 mg administered over 5 minutes followed by infusion at 2 mg/h for 15.6 +/- 6.4 hours; total dose, 51 +/- 16 mg), successful thrombolysis was achieved in 84% of the patients. The primary patency rate was 75% and the secondary patency rate 100% at 16 weeks. One patient underwent amputation owing to unsuccessful thrombolysis. No major bleeding or vascular complications occurred. We conclude that intra-arterial thrombolysis using rt-PA is a safe and effective therapy for patients with thrombotic occlusion of synthetic lower extremity bypass grafts presenting with acute limb-threatening ischemia and allows a high rate of secondary patency, avoiding amputation.

AB - Occlusion of lower extremity vascular bypass grafts results in acute limb-threatening ischemia. The underlying cause of graft failure generally is distal anastomosis stenosis, and relief of culprit stenosis is a required to maintain long-term patency. Of the three thrombolytic agents used for prolonged infusion to accomplish fibrinolysis, streptokinase was the first to be used and is limited owing to the antigenicity that precludes repeated use. Urokinase had been the mainstay of thrombolytic therapy until it was withdrawn by the U.S. Food and Drug Administration in 1999 because of the potential of transmission of infectious agents during its manufacturing process. Recombinant tissue plasminogen activator (rt-PA) has not been studied adequately to assess safety and efficacy, and there are no standardized dosing guidelines. We report our experience with six patients presenting with acute limb-threatening ischemia attributable to thrombosis of synthetic lower extremity bypass grafts. After thrombolysis using rt-PA (mean bolus dose, 12.2 +/- 3.6 mg; range, 6-15 mg administered over 5 minutes followed by infusion at 2 mg/h for 15.6 +/- 6.4 hours; total dose, 51 +/- 16 mg), successful thrombolysis was achieved in 84% of the patients. The primary patency rate was 75% and the secondary patency rate 100% at 16 weeks. One patient underwent amputation owing to unsuccessful thrombolysis. No major bleeding or vascular complications occurred. We conclude that intra-arterial thrombolysis using rt-PA is a safe and effective therapy for patients with thrombotic occlusion of synthetic lower extremity bypass grafts presenting with acute limb-threatening ischemia and allows a high rate of secondary patency, avoiding amputation.

UR - http://www.scopus.com/inward/record.url?scp=0037261709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037261709&partnerID=8YFLogxK

U2 - 10.1097/00045391-200301000-00003

DO - 10.1097/00045391-200301000-00003

M3 - Article

C2 - 12522513

AN - SCOPUS:0037261709

VL - 10

SP - 3

EP - 6

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -